Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Importance: The use of sacubitril/valsartan is not endorsed by practice guidelines for use in patients with New York Heart Association class IV heart failure with a reduced ejection fraction because of limited clinical experience in this population. Objective: To compare treatment with sacubitril/valsartan treatment with valsartan in patients with advanced heart failure and a reduced ejection fraction and recent New York Heart Association class IV symptoms. Design, Setting, and Participants: A double-blind randomized clinical trial was conducted; a total of 335 patients with advanced heart failure were included. The trial began on March 2, 2017, and was stopped early on March 23, 2020, owing to COVID-19 risk. Intervention: Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or valsartan (target dose, 160 mg twice daily) in addition to recommended therapy. Main Outcomes and Measures: The area under the curve (AUC) for the ratio of N-terminal pro-brain natriuretic peptide (NT-proBNP) compared with baseline measured through 24 weeks of therapy. Results: Of the 335 patients included in the analysis, 245 were men (73%); mean (SD) age was 59.4 (13.5) years. Seventy-two eligible patients (18%) were not able to tolerate sacubitril/valsartan, 100 mg/d, during the short run-in period, and 49 patients (29%) discontinued sacubitril/valsartan during the 24 weeks of the trial. The median NT-proBNP AUC for the valsartan treatment arm (n = 168) was 1.19 (IQR, 0.91-1.64), whereas the AUC for the sacubitril/valsartan treatment arm (n = 167) was 1.08 (IQR, 0.75-1.60). The estimated ratio of change in the NT-proBNP AUC was 0.95 (95% CI 0.84-1.08; P = .45). Compared with valsartan, treatment with sacubitril/valsartan did not improve the clinical composite of number of days alive, out of hospital, and free from heart failure events. Aside from a statistically significant increase in non-life-threatening hyperkalemia in the sacubitril/valsartan arm (28 [17%] vs 15 [9%]; P = .04), there were no observed safety concerns. Conclusions and Relevance: The findings of this trial showed that, in patients with chronic advanced heart failure with a reduced ejection fraction, there was no statistically significant difference between sacubitril/valsartan and valsartan with respect to reducing NT-proBNP levels. Trial Registration: ClinicalTrials.gov Identifier: NCT02816736.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citation2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Angiotensin-neprilysin inhibition in acute decompensated heart failure
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812851 · Cited by 1,260
Self-citation
Cited by
Semaglutide and NT-proBNP in Obesity-Related HFpEF
Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.022 · Cited by 95
Metadata
- Authors
- Mann, D. L., Givertz, M. M., Vader, J. M., Starling, R. C., Shah, P., McNulty, S. E., Anstrom, K. J., Margulies, K. B., Kiernan, M. S., Mahr, C., Gupta, D., Redfield, M. M., Lala, A., Lewis, G. D., DeVore, A. D., Desvigne-Nickens, P., Hernandez, A. F., Braunwald, E., LIFE Investigators, Mohammed, S. F., Birru, H., Aboye, E., Lam, P. H., Escobar, N., Fink, M., Cappola, T. P., Sheaffer, W., Reilly, B., Ferree, J., Ravichandran, A. K., Ciezkowski, G., Herrera, G., Mehta, H. S., DeLucca, R., Doddamani, S., Kanwar, M., Thomas, B., Machen, L., Kim, J., Christina, A., Lampert, B. C., Fontenelle, C., Eiswirth, C. C., Williams, J., Rock, D., Egnaczyk, G. F., Rentas-Sherman, E., Barr, D., Bhimaraj, A., Damato, A., Calayo, C., Herre, J. M., Lindenfeld, J., Carroll, A., Gordon, M., Keebler, M. E., Setliff, B., Gulati, S. K., Winkler, K., Curtin, L., Ohmart, C., Halvorson, J., Mudd, J. O., Camacho, S. A., Palardy, M., Shah, N., Picardi, K., Krishnamoorthy, A., Maximin, A., Horstmanshof, D. A., Seiler, B., Xu, Z. J., Mersola, S., Kransdorf, E. P., Tang, W., Fonk, T., Gorodeski, E. Z., Oliveira, G. H., Semenec, T., Norton, N., Nichols, J., Leo, P., Dunlap, M. E., Felker, G. M., Taylor, L., Sheehan, M., Levine, S., Cocca-Spofford, D., Brooks, L., Cunningham, T., Acker, N., Milbrandt, S., Gatzke, J., Davila-Roman, V. G., Dirks, A., Bult, K., Weber, E., Lesko, M., Mikhalkova, D., Fitzgerald, K., Whellan, D. J., Wever-Pinzon, O., Gutierrez, J., Goldsborough, Y., Gilotra, N. A., Caikauskaite, I., Skopicki, H. A., Huggins, G. S., Yuen, N., Haynes, A., Katie, C., Snell, G., Smith, A. L., Walker, B., Johnson, J., Henderson, S., Pauwaa, S., Bhat, G., & Gagliardi, A.
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2022-01-01
- Volume
- 7
- Issue
- 1
- Pages
- 17
- ISSN
- 2380-6583 (ISSN-L)
- OpenAlex
- W3208470283
- Cited by
- 178
- References
- 6
- FWCI
- 18.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamacardio.2021.4567
- The paper
- Mann, D. L., Givertz, M. M., Vader, J. M., Starling, R. C., Shah, P., McNulty, S. E., Anstrom, K. J., Margulies, K. B., Kiernan, M. S., Mahr, C., Gupta, D., Redfield, M. M., Lala, A., Lewis, G. D., DeVore, A. D., Desvigne-Nickens, P., Hernandez, A. F., Braunwald, E., LIFE Investigators, . . . Gagliardi, A. (2022). Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2021.4567
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.